Koligo Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $14.5M

  • Investors
  • 1

Koligo Therapeutics General Information

Description

Koligo Therapeutics Ltd is a biotechnology company based in Australia. It is focused on treating chronic pancreatitis, Type 1 Diabetes and Other Pancreatic diseases. The company has developed Kyslecel which is used in the treatment of patients suffering from chronic or acuterecurrent pancreatitis, a debilitating and painful condition with less treatment options.

Contact Information

Website
www.koligo.net
Ownership Status
Acquired/Merged
Financing Status
Formerly Angel backed
Corporate Office
  • 204 South Floyd Street
  • Louisville, KY
  • United States
+1 (502)
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 204 South Floyd Street
  • Louisville, KY
  • United States
+1 (502)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Koligo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 15-Oct-2020 $14.5M Completed Generating Revenue
3. IPO 11-Apr-2019 Completed Generating Revenue
2. Mezzanine 07-Mar-2018 $2M $2M Completed Generating Revenue
1. Angel (individual) 13-Dec-2017 $5K $5K Completed Startup
To view Koligo Therapeutics’s complete valuation and funding history, request access »

Koligo Therapeutics Patents

Koligo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018452704-A1 Cell separation apparatus and methods of use Inactive 13-Dec-2018
EP-3893949-A1 Cell separation apparatus and methods of use Inactive 13-Dec-2018
EP-3893949-A4 Cell separation apparatus and methods of use Inactive 13-Dec-2018
US-20110218396-A1 Methods and compositions to support tissue integration and inosculation of transplanted tissue and transplanted engineered penile tissue with adipose stromal cells Active 05-Mar-2010
US-8727965-B2 Methods and compositions to support tissue integration and inosculation of transplanted tissue and transplanted engineered penile tissue with adipose stromal cells Active 05-Mar-2010 A61F2/26
To view Koligo Therapeutics’s complete patent history, request access »

Koligo Therapeutics FAQs

  • When was Koligo Therapeutics founded?

    Koligo Therapeutics was founded in 2016.

  • Where is Koligo Therapeutics headquartered?

    Koligo Therapeutics is headquartered in Louisville, KY.

  • What industry is Koligo Therapeutics in?

    Koligo Therapeutics’s primary industry is Laboratory Services (Healthcare).

  • Is Koligo Therapeutics a private or public company?

    Koligo Therapeutics is a Private company.

  • What is the current valuation of Koligo Therapeutics?

    The current valuation of Koligo Therapeutics is .

  • What is Koligo Therapeutics’s current revenue?

    The current revenue for Koligo Therapeutics is .

  • How much funding has Koligo Therapeutics raised over time?

    Koligo Therapeutics has raised $6.26M.

  • When was Koligo Therapeutics acquired?

    Koligo Therapeutics was acquired on 15-Oct-2020.

  • Who acquired Koligo Therapeutics?

    Koligo Therapeutics was acquired by Orgenesis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process